Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study

Kevin L Schwartz1, Ilyse Darwish, Susan E Richardson

  • 1Division of Infectious Diseases, The Hospital for Sick Children, University of Toronto, 555 University Ave, Rm 7306, Toronto, ON M5G 1X8, Canada. Kevin.schwartz@sickkids.ca.

BMC Pediatrics
|February 4, 2014
PubMed

Insights

Severe outcomes from Clostridium difficile infection (CDI) are rare in children, with most cases resolving within 30 days. Further research is needed to understand risk factors and treatment for pediatric CDI.

Area of Science:

  • Pediatric Infectious Diseases
  • Gastroenterology
  • Epidemiology

Background:

  • Clostridium difficile infection (CDI) is a leading cause of healthcare-associated diarrhea in children and adults.
  • While severe CDI complications are rising in adults, this trend is not established in pediatric populations.
  • This study investigates pediatric CDI features, focusing on severe outcomes.

Purpose of the Study:

  • To examine the clinical features of Clostridium difficile infection (CDI) in children.
  • To determine the incidence of severe outcomes in pediatric CDI cases.
  • To identify potential risk factors and strain characteristics associated with pediatric CDI.

Main Methods:

  • Retrospective chart review of pediatric patients diagnosed with CDI via cytotoxin assay (August 2008-July 2012).
  • Data collection included demographics, acquisition source, clinical/laboratory findings, treatment, and outcomes.
  • Isolates underwent pulsed-field gel electrophoresis and toxin gene analysis (tcdA, tcdB, cdtB, tcdC).

Main Results:

  • Ninety percent of pediatric CDI cases resolved within 30 days; only 2% experienced severe outcomes.
  • No colectomies were performed, and only one death was linked to CDI.
  • Nosocomial acquisition accounted for 74% of cases. NAP4 was the most frequent strain (24%), associated with higher relapse rates but not severe outcomes.

Conclusions:

  • Severe outcomes from Clostridium difficile infection (CDI) are infrequent in children compared to adults.
  • Prospective studies are needed to elucidate pediatric CDI risk factors, optimal treatments, and the role of specific strains like NAP4.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
90
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
33